Early lesion-specific 18F-FDG PET response to chemotherapy predicts time to lesion progression in locally advanced non-small cell lung cancer. Issue 3 (March 2016)

• Record Type: Journal Article
• Authors: Nygård, Lotte; Vogelius, Ivan R.; Fischer, Barbara M.; Klausen, Thomas L.; Langer, Seppo W.; Lonsdale, Markus N.; Persson, Gitte F.; Bentzen, Søren M.
• Is Part Of: Radiotherapy and oncology. Volume 118:Issue 3(2016:Mar.)
• Page Start: 460
• Page End: 464
• Publication Date: 2016-03
• Subjects: Lung cancer -- FDG PET -- Early response; Oncology -- Periodicals; Radiotherapy -- Periodicals; Tumors -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- radiotherapy -- Periodicals; Radiotherapy -- Periodicals; Radiothérapie -- Périodiques; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9940642
• DOI: 10.1016/j.radonc.2016.01.009
• Languages: English
• ISSNs: 0167-8140

Abstract

Abstract: Background and purpose: We hypothesize that the lesion-to-lesion variability in FDG-PET response after one cycle of chemotherapy for NSCLC in an individual patient may inform radiation dose redistribution. To test this hypothesis, we investigate if time to lesion-progression in patients with multiple lesions is dependent on lesion-specific response to chemotherapy. Materials and methods: We analyzed 81 patients with 184 lesions referred to curative chemo-radiotherapy for NSCLC 2010–2012. 18 F-FDG PET scans were performed at diagnosis and after one series of chemotherapy. Response of each lesion was assessed as the change in FDG peak standardized uptake value. Variance of lesion response was compared within and between patients. Time to progression for each lesion was analyzed using the Kaplan–Meier method and the Cox proportional hazards model. Results: Within-patient variability in lesion responses was of the same magnitude as the between-patient variability. Lesion-specific time to progression was longer in lesions with a better response (log-rank p = 0.038). Nodal lesions had a much lower risk of progression than T-site lesions (HR = 0.09, p < 0.0001). Conclusions: Recording an overall patient response involves a loss of biological information on heterogeneity between lesions. Poor lesion-specific response after one cycle chemotherapy may identify lesions that would benefit from an individualized radiotherapy strategy.